Intrinsic value of Natus Medical - BABY

Previous Close

$35.85

  Intrinsic Value

$168.08

stock screener

  Rating & Target

str. buy

+369%

  Value-price divergence*

-4%

Previous close

$35.85

 
Intrinsic value

$168.08

 
Up/down potential

+369%

 
Rating

str. buy

 
Value-price divergence*

-4%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of BABY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  1.60
  43.70
  39.83
  36.35
  33.21
  30.39
  27.85
  25.57
  23.51
  21.66
  19.99
  18.49
  17.14
  15.93
  14.84
  13.85
  12.97
  12.17
  11.45
  10.81
  10.23
  9.71
  9.23
  8.81
  8.43
  8.09
  7.78
  7.50
  7.25
  7.03
  6.82
Revenue, $m
  382
  549
  768
  1,047
  1,394
  1,818
  2,324
  2,918
  3,604
  4,385
  5,262
  6,235
  7,304
  8,468
  9,724
  11,071
  12,507
  14,029
  15,636
  17,326
  19,098
  20,951
  22,886
  24,902
  27,002
  29,185
  31,455
  33,815
  36,266
  38,814
  41,463
Variable operating expenses, $m
 
  452
  627
  851
  1,130
  1,470
  1,876
  2,353
  2,904
  3,530
  4,234
  5,003
  5,861
  6,795
  7,803
  8,884
  10,036
  11,257
  12,546
  13,902
  15,324
  16,812
  18,364
  19,982
  21,667
  23,419
  25,240
  27,134
  29,101
  31,145
  33,270
Fixed operating expenses, $m
 
  9
  9
  10
  10
  10
  10
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  14
  14
  14
  15
  15
  15
  16
  16
  17
  17
  18
  18
  18
  19
Total operating expenses, $m
  327
  461
  636
  861
  1,140
  1,480
  1,886
  2,364
  2,915
  3,541
  4,246
  5,015
  5,873
  6,807
  7,816
  8,897
  10,049
  11,271
  12,560
  13,916
  15,339
  16,827
  18,379
  19,998
  21,683
  23,436
  25,257
  27,152
  29,119
  31,163
  33,289
Operating income, $m
  55
  88
  131
  186
  254
  338
  437
  555
  690
  844
  1,017
  1,220
  1,431
  1,661
  1,909
  2,174
  2,458
  2,758
  3,075
  3,409
  3,759
  4,124
  4,506
  4,904
  5,319
  5,750
  6,198
  6,664
  7,148
  7,651
  8,173
EBITDA, $m
  72
  111
  158
  219
  295
  387
  498
  627
  777
  947
  1,139
  1,351
  1,584
  1,838
  2,113
  2,407
  2,720
  3,052
  3,403
  3,772
  4,159
  4,564
  4,986
  5,427
  5,885
  6,362
  6,858
  7,373
  7,908
  8,465
  9,043
Interest expense (income), $m
  0
  5
  8
  13
  19
  26
  35
  46
  59
  73
  90
  109
  129
  152
  177
  204
  232
  263
  295
  329
  365
  403
  442
  483
  526
  571
  617
  666
  716
  768
  822
Earnings before tax, $m
  55
  83
  122
  173
  235
  311
  402
  508
  631
  770
  927
  1,111
  1,302
  1,509
  1,732
  1,971
  2,226
  2,495
  2,780
  3,080
  3,393
  3,722
  4,064
  4,421
  4,792
  5,179
  5,581
  5,998
  6,432
  6,883
  7,351
Tax expense, $m
  12
  22
  33
  47
  64
  84
  109
  137
  170
  208
  250
  300
  351
  407
  468
  532
  601
  674
  751
  831
  916
  1,005
  1,097
  1,194
  1,294
  1,398
  1,507
  1,619
  1,737
  1,858
  1,985
Net income, $m
  43
  61
  89
  126
  172
  227
  293
  371
  461
  562
  677
  811
  950
  1,101
  1,264
  1,439
  1,625
  1,822
  2,030
  2,248
  2,477
  2,717
  2,967
  3,227
  3,498
  3,781
  4,074
  4,379
  4,695
  5,024
  5,366

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  248
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  649
  576
  805
  1,098
  1,463
  1,908
  2,439
  3,062
  3,782
  4,601
  5,521
  6,543
  7,664
  8,885
  10,203
  11,617
  13,123
  14,721
  16,407
  18,180
  20,040
  21,984
  24,015
  26,131
  28,333
  30,625
  33,007
  35,482
  38,055
  40,729
  43,507
Adjusted assets (=assets-cash), $m
  401
  576
  805
  1,098
  1,463
  1,908
  2,439
  3,062
  3,782
  4,601
  5,521
  6,543
  7,664
  8,885
  10,203
  11,617
  13,123
  14,721
  16,407
  18,180
  20,040
  21,984
  24,015
  26,131
  28,333
  30,625
  33,007
  35,482
  38,055
  40,729
  43,507
Revenue / Adjusted assets
  0.953
  0.953
  0.954
  0.954
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
  0.953
Average production assets, $m
  99
  142
  198
  270
  360
  469
  600
  753
  930
  1,131
  1,358
  1,609
  1,884
  2,185
  2,509
  2,856
  3,227
  3,619
  4,034
  4,470
  4,927
  5,405
  5,905
  6,425
  6,966
  7,530
  8,116
  8,724
  9,357
  10,014
  10,697
Working capital, $m
  326
  112
  157
  213
  284
  371
  474
  595
  735
  895
  1,073
  1,272
  1,490
  1,727
  1,984
  2,258
  2,551
  2,862
  3,190
  3,534
  3,896
  4,274
  4,669
  5,080
  5,508
  5,954
  6,417
  6,898
  7,398
  7,918
  8,458
Total debt, $m
  140
  242
  374
  544
  755
  1,012
  1,320
  1,681
  2,098
  2,572
  3,105
  3,696
  4,346
  5,052
  5,816
  6,634
  7,506
  8,431
  9,408
  10,434
  11,511
  12,637
  13,812
  15,038
  16,313
  17,640
  19,019
  20,452
  21,942
  23,490
  25,099
Total liabilities, $m
  232
  334
  466
  636
  847
  1,104
  1,412
  1,773
  2,190
  2,664
  3,197
  3,788
  4,438
  5,144
  5,908
  6,726
  7,598
  8,523
  9,500
  10,526
  11,603
  12,729
  13,904
  15,130
  16,405
  17,732
  19,111
  20,544
  22,034
  23,582
  25,191
Total equity, $m
  417
  242
  339
  462
  616
  803
  1,027
  1,289
  1,592
  1,937
  2,325
  2,754
  3,227
  3,741
  4,296
  4,891
  5,525
  6,197
  6,907
  7,654
  8,437
  9,255
  10,110
  11,001
  11,928
  12,893
  13,896
  14,938
  16,021
  17,147
  18,317
Total liabilities and equity, $m
  649
  576
  805
  1,098
  1,463
  1,907
  2,439
  3,062
  3,782
  4,601
  5,522
  6,542
  7,665
  8,885
  10,204
  11,617
  13,123
  14,720
  16,407
  18,180
  20,040
  21,984
  24,014
  26,131
  28,333
  30,625
  33,007
  35,482
  38,055
  40,729
  43,508
Debt-to-equity ratio
  0.336
  1.000
  1.100
  1.180
  1.230
  1.260
  1.290
  1.300
  1.320
  1.330
  1.340
  1.340
  1.350
  1.350
  1.350
  1.360
  1.360
  1.360
  1.360
  1.360
  1.360
  1.370
  1.370
  1.370
  1.370
  1.370
  1.370
  1.370
  1.370
  1.370
  1.370
Adjusted equity ratio
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421
  0.421

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  43
  61
  89
  126
  172
  227
  293
  371
  461
  562
  677
  811
  950
  1,101
  1,264
  1,439
  1,625
  1,822
  2,030
  2,248
  2,477
  2,717
  2,967
  3,227
  3,498
  3,781
  4,074
  4,379
  4,695
  5,024
  5,366
Depreciation, amort., depletion, $m
  17
  23
  27
  33
  41
  49
  60
  73
  87
  103
  122
  131
  153
  178
  204
  232
  262
  294
  328
  363
  401
  439
  480
  522
  566
  612
  660
  709
  761
  814
  870
Funds from operations, $m
  76
  83
  117
  159
  212
  277
  354
  444
  548
  666
  798
  942
  1,103
  1,279
  1,468
  1,671
  1,887
  2,116
  2,358
  2,612
  2,878
  3,156
  3,447
  3,750
  4,065
  4,393
  4,734
  5,088
  5,456
  5,838
  6,236
Change in working capital, $m
  3
  34
  45
  57
  71
  86
  103
  121
  140
  159
  179
  199
  218
  237
  256
  275
  293
  311
  328
  345
  361
  378
  395
  411
  428
  445
  463
  481
  500
  520
  540
Cash from operations, $m
  73
  49
  72
  102
  141
  190
  250
  322
  408
  506
  619
  744
  885
  1,041
  1,212
  1,396
  1,594
  1,805
  2,030
  2,267
  2,516
  2,778
  3,052
  3,338
  3,637
  3,947
  4,270
  4,607
  4,956
  5,319
  5,696
Maintenance CAPEX, $m
  0
  -8
  -12
  -16
  -22
  -29
  -38
  -49
  -61
  -76
  -92
  -110
  -131
  -153
  -178
  -204
  -232
  -262
  -294
  -328
  -363
  -401
  -439
  -480
  -522
  -566
  -612
  -660
  -709
  -761
  -814
New CAPEX, $m
  -3
  -43
  -56
  -72
  -90
  -109
  -131
  -153
  -177
  -201
  -226
  -251
  -276
  -300
  -324
  -348
  -370
  -393
  -415
  -436
  -457
  -478
  -499
  -520
  -542
  -563
  -586
  -609
  -633
  -657
  -683
Cash from investing activities, $m
  -53
  -51
  -68
  -88
  -112
  -138
  -169
  -202
  -238
  -277
  -318
  -361
  -407
  -453
  -502
  -552
  -602
  -655
  -709
  -764
  -820
  -879
  -938
  -1,000
  -1,064
  -1,129
  -1,198
  -1,269
  -1,342
  -1,418
  -1,497
Free cash flow, $m
  20
  -2
  4
  14
  30
  52
  81
  120
  169
  229
  301
  382
  479
  588
  710
  845
  991
  1,150
  1,321
  1,503
  1,696
  1,899
  2,113
  2,338
  2,573
  2,818
  3,073
  3,338
  3,614
  3,901
  4,198
Issuance/(repayment) of debt, $m
  140
  102
  133
  170
  211
  257
  308
  361
  417
  474
  533
  591
  649
  707
  763
  818
  872
  925
  976
  1,027
  1,077
  1,126
  1,175
  1,225
  1,275
  1,327
  1,379
  1,433
  1,490
  1,548
  1,609
Issuance/(repurchase) of shares, $m
  -16
  13
  7
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  118
  115
  140
  170
  211
  257
  308
  361
  417
  474
  533
  591
  649
  707
  763
  818
  872
  925
  976
  1,027
  1,077
  1,126
  1,175
  1,225
  1,275
  1,327
  1,379
  1,433
  1,490
  1,548
  1,609
Total cash flow (excl. dividends), $m
  131
  113
  144
  184
  241
  309
  389
  481
  586
  704
  834
  973
  1,128
  1,295
  1,473
  1,663
  1,864
  2,075
  2,297
  2,530
  2,772
  3,025
  3,289
  3,563
  3,848
  4,144
  4,452
  4,771
  5,103
  5,449
  5,807
Retained Cash Flow (-), $m
  -26
  -73
  -97
  -123
  -154
  -187
  -224
  -263
  -303
  -345
  -387
  -430
  -472
  -514
  -555
  -595
  -634
  -672
  -710
  -747
  -783
  -819
  -855
  -891
  -927
  -965
  -1,003
  -1,042
  -1,083
  -1,126
  -1,170
Prev. year cash balance distribution, $m
 
  248
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  287
  48
  61
  87
  122
  165
  219
  283
  359
  447
  544
  656
  781
  918
  1,068
  1,229
  1,403
  1,587
  1,783
  1,989
  2,207
  2,434
  2,672
  2,921
  3,180
  3,449
  3,729
  4,020
  4,323
  4,637
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  275
  44
  53
  72
  94
  120
  148
  177
  206
  234
  258
  280
  297
  308
  314
  312
  305
  292
  275
  253
  228
  202
  175
  149
  124
  101
  80
  62
  47
  35
Current shareholders' claim on cash, %
  100
  97.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3
  96.3

Natus Medical Incorporated designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. It offers neurology products, such as diagnostic electroencephalography and long-term monitoring products, electrodiagnostic monitoring products, diagnostic polysomnography monitoring products, diagnostic intraoperative monitoring products, and transcranial Doppler products. The company also provides newborn care products, including hearing screening products to screen the hearing; brain injury products to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity, and monitor general neurological status; and thermoregulation products to control the newborn environment, including incubators and warmers. Its newborn care also comprise jaundice management products to measure bilirubin levels and treat jaundice; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages; balance and mobility systems to diagnose and assist in treating balance disorders; and NicView video for families with babies in the neonatal intensive care unit. The company serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in Pleasanton, California.

FINANCIAL RATIOS  of  Natus Medical (BABY)

Valuation Ratios
P/E Ratio 27.4
Price to Sales 3.1
Price to Book 2.8
Price to Tangible Book
Price to Cash Flow 16.2
Price to Free Cash Flow 16.9
Growth Rates
Sales Growth Rate 1.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -40%
Cap. Spend. - 3 Yr. Gr. Rate -5.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 33.6%
Total Debt to Equity 33.6%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.6%
Ret/ On Assets - 3 Yr. Avg. 7.8%
Return On Total Capital 9.1%
Ret/ On T. Cap. - 3 Yr. Avg. 9.5%
Return On Equity 10.6%
Return On Equity - 3 Yr. Avg. 10.2%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 61.5%
Gross Margin - 3 Yr. Avg. 60.8%
EBITDA Margin 18.8%
EBITDA Margin - 3 Yr. Avg. 17.7%
Operating Margin 14.4%
Oper. Margin - 3 Yr. Avg. 13.9%
Pre-Tax Margin 14.4%
Pre-Tax Margin - 3 Yr. Avg. 13.7%
Net Profit Margin 11.3%
Net Profit Margin - 3 Yr. Avg. 10.1%
Effective Tax Rate 21.8%
Eff/ Tax Rate - 3 Yr. Avg. 26.4%
Payout Ratio 0%

BABY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BABY stock intrinsic value calculation we used $382 million for the last fiscal year's total revenue generated by Natus Medical. The default revenue input number comes from 2016 income statement of Natus Medical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BABY stock valuation model: a) initial revenue growth rate of 43.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BABY is calculated based on our internal credit rating of Natus Medical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Natus Medical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BABY stock the variable cost ratio is equal to 83.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $9 million in the base year in the intrinsic value calculation for BABY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Natus Medical.

Corporate tax rate of 27% is the nominal tax rate for Natus Medical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BABY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BABY are equal to 25.8%.

Life of production assets of 12.3 years is the average useful life of capital assets used in Natus Medical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BABY is equal to 20.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $417 million for Natus Medical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 32.068 million for Natus Medical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Natus Medical at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
NURO NeuroMetrix 1.94 0.17  str.sell
CASM CAS Medical Sy 1.18 0.03  str.sell
MASI Masimo 95.53 41.50  str.sell
GE General Electr 25.79 16.08  sell
HOLX Hologic 44.44 16.08  str.sell
BDX Becton Dickins 201.67 58.16  str.sell
PHG Koninklijke Ph 38.02 20.15  sell

COMPANY NEWS

▶ Natus Medical Inc Looks to Turn Things Around   [Jul-27-17 02:30PM  Motley Fool]
▶ Natus Medical reports 2Q loss   [Jul-26-17 09:54PM  Associated Press]
▶ ETFs with exposure to Natus Medical, Inc. : July 13, 2017   [Jul-13-17 03:34PM  Capital Cube]
▶ ETFs with exposure to Natus Medical, Inc. : June 27, 2017   [Jun-27-17 02:56PM  Capital Cube]
▶ Today's Bell Ringer, June 21, 2107   [Jun-21-17 09:19AM  CNBC Videos]
▶ ETFs with exposure to Natus Medical, Inc. : June 15, 2017   [Jun-15-17 01:12PM  Capital Cube]
▶ Natus to Present at Jefferies 2017 Healthcare Conference   [May-30-17 07:00AM  GlobeNewswire]
▶ Natus Medical to Host Analyst Day on June 22nd   [May-11-17 07:00AM  GlobeNewswire]
▶ Natus Medical Inc. Fell 11% in April. Here's Why.   [May-08-17 03:49PM  Motley Fool]
▶ Why Natus Medical Inc. Sank Today   [Apr-26-17 12:44PM  Motley Fool]
▶ Natus Medical misses 1Q profit forecasts   [08:10AM  Associated Press]
▶ 3 Top Medical Device Stocks to Buy in 2017   [03:02PM  at Motley Fool]
▶ Natus to Present at 29th Annual Roth Conference   [Mar-01-17 07:00AM  GlobeNewswire]
Stock chart of BABY Financial statements of BABY Annual reports of BABY
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.